ADC Toxicity: Exploring In Vivo Strategies & Clinical Topo1 Outcomes
- Understanding state-of-play in NHP studies and implications for ADCs in the clinic
- Investigating top-line Topo1 asset toxicity data and considering impact on the ADC space
- Reviewing FIH trial adverse event data to help visualize the Topo1 toxicity landscape